Nicorandil - an Effective Multitarget Drug for Cardioprotection?

Cardiovasc Drugs Ther. 2023 Feb;37(1):5-8. doi: 10.1007/s10557-022-07397-x. Epub 2022 Oct 27.

Authors

Lucie Pearce¹, Richard D Carr¹, Derek M Yellon¹, Sean M Davidson²

Affiliations

¹ The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
² The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK. s.davidson@ucl.ac.uk.

PMID: 36301452
DOI: 10.1007/s10557-022-07397-x

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Myocardial Reperfusion Injury* / prevention & control
Nicorandil* / pharmacology
Nicorandil* / therapeutic use
Oxidative Stress
Vasodilator Agents / pharmacology

Substances

Nicorandil
Vasodilator Agents

Grants and funding